Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FUCA1 | P04066 | 2/20 | 0.45 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.40 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.40 |
| ▸ | KDM1A | O60341 | 2/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | EBP | Q15125 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.37 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.36 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13819197 | 1.00 | FUCA1 (0.45) | FUCA1OPRM1OPRL1KDM1AMAOA | |
| SCHEMBL26319083 | 1.00 | FUCA1 (0.45) | FUCA1OPRM1OPRL1KDM1AMAOA | |
| SCHEMBL3507722 | 1.00 | FUCA1 (0.45) | FUCA1OPRM1OPRL1KDM1AMAOA | |
| SCHEMBL30532010 | 1.00 | FUCA1 (0.45) | FUCA1OPRM1OPRL1KDM1AMAOA | |
| SCHEMBL31363766 | 0.85 | KDM1A (0.44) | KDM1AMAOA | |
| SCHEMBL1134383 | 0.81 | FUCA1 (0.42) | FUCA1OPRM1OPRL1KDM1AMAOA | |
| SCHEMBL1134381 | 0.81 | FUCA1 (0.42) | FUCA1OPRM1OPRL1KDM1AMAOA | |
| SCHEMBL1134382 | 0.81 | FUCA1 (0.42) | FUCA1OPRM1OPRL1KDM1AMAOA | |
| SCHEMBL803482 | 0.77 | OPRM1 (0.56) | OPRM1OPRL1GRIN2B | |
| SCHEMBL9729099 | 0.77 | CCR1 (0.40) | SIGMAR1GRM2GRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4479137-A1 | IRAK4 INHIBITORS | Astrazeneca AB (SE) | 2024-12-25 | — | — | EP | disclosed |
| US-20240360114-A1 | FERROPTOSIS MODULATORS, PREPARATIONS, AND USES THEREOF | Sironax Ltd. (KY) | 2024-10-31 | — | — | US | disclosed |
| CN-118591536-A | IRAK4 inhibitors | 阿斯利康(瑞典)有限公司 | 2024-09-03 | — | — | CN | disclosed |
| EP-4384493-A1 | FERROPTOSIS MODULATORS, PREPARATIONS, AND USES THEREOF | Sironax Ltd (KY) | 2024-06-19 | — | — | EP | disclosed |
| CN-118076581-A | Iron death modulators, their preparation and use | 维泰瑞隆有限公司 | 2024-05-24 | — | — | CN | disclosed |
| WO-2023152349-A1 | IRAK4 INHIBITORS | ASTRAZENECA AB (SE) | 2023-08-17 | — | — | WO | disclosed |
| WO-2023152349-A1 | IRAK4 INHIBITORS | ASTRAZENECA AB (SE) | 2023-08-17 | — | — | WO | disclosed |
| WO-2023016447-A1 | FERROPTOSIS MODULATORS, PREPARATIONS, AND USES THEREOF | Sironax Ltd. (KY) | 2023-02-16 | — | — | WO | disclosed |
| EP-3200789-B1 | INHIBITORS OF IRAK4 ACTIVITY | MERCK SHARP & DOHME (US) | 2019-11-06 | — | — | EP | disclosed |
| US-9932350-B2 | Inhibitors of IRAK4 activity | MERCK SHARP & DOHME CORP. (US) | 2018-04-03 | — | — | US | disclosed |
| EP-3200789-A1 | INHIBITORS OF IRAK4 ACTIVITY | Merck Sharp & Dohme Corp. (US) | 2017-08-09 | — | — | EP | disclosed |
| US-20170217981-A1 | INHIBITORS OF IRAK4 ACTIVITY | MERCK SHARP & DOHME CORP. (US) | 2017-08-03 | — | — | US | disclosed |
| WO-2016053772-A1 | INHIBITORS OF IRAK4 ACTIVITY | MERCK SHARP & DOHME CORP. (US) | 2016-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240360114-A1 | FERROPTOSIS MODULATORS, PREPARATIONS, AND USES THEREOF | AIFM2, GPX1, GPX4 | FUCA1 2005/4885OPRM1 2385/4885OPRL1 3460/4885 |
| US-20170217981-A1 | INHIBITORS OF IRAK4 ACTIVITY | IRAK4, IRAK1, IRAK2 | FUCA1 4164/4885OPRM1 4319/4885OPRL1 2510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.